Daratumumab monotherapy in heavily pretreated Asians patients with relapsed and refractory multiple myeloma

被引：0
|
作者：
Yoon, Sung-Soo [1 ]
Byun, Ja Min [1 ]
Park, Hyunkyung [2 ]
Lee, Ji Yun [3 ]
Koh, Youngil [1 ]
机构：
[1] Seoul Natl Univ Hosp, Seoul, South Korea
[2] Seoul Natl Univ, Boramae Med Ctr, Seoul, South Korea
[3] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
Asia; daratumumab; real-world evidence;
D O I：
10.1016/j.clml.2019.09.259
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FP-174
引用
收藏
页码：E155 / E156
页数：2
相关论文
共 50 条
  • [1] Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
    Usmani, Saad
    Weiss, Brendan
    Bahlis, Nizar J.
    Belch, Andrew
    Lonial, Sagar
    Lokhorst, Henk
    Voorhees, Peter M.
    Richardson, Paul G.
    Sasser, A. Kate
    Axel, Amy
    Feng, Huaibao
    Uhlar, Clarissa
    Wang, Jianping
    Khan, Imran
    Ahmadi, Tahamtan
    Nahi, Hareth
    BLOOD, 2015, 126 (23)
  • [2] Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
    Usmani, Saad Z.
    Weiss, Brendan M.
    Plesner, Torben
    Bahlis, Nizar J.
    Belch, Andrew
    Lonial, Sagar
    Lokhorst, Henk M.
    Voorhees, Peter M.
    Richardson, Paul G.
    Chari, Ajai
    Sasser, A. Kate
    Axel, Amy
    Feng, Huaibao
    Uhlar, Clarissa M.
    Wang, Jianping
    Khan, Imran
    Ahmadi, Tahamtan
    Nahi, Hareth
    BLOOD, 2016, 128 (01) : 37 - 44
  • [3] Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma
    Salomon-Perzynski, Aleksander
    Walter-Croneck, Adam
    Usnarska-Zubkiewicz, Lidia
    Dytfeld, Dominik
    Zielinska, Patrycja
    Wojciechowska, Malgorzata
    Holojda, Jadwiga
    Robak, Pawel
    Pasternak, Anna
    Knopinska-Posluszny, Wanda
    Hawrylecka, Dorota
    Wojtowicz, Marcin
    Szeremet, Agnieszka
    Osowiecki, Michal
    Mordak-Domagala, Monika
    Zaucha, Jan Maciej
    Giannopoulos, Krzysztof
    Warzocha, Krzysztof
    Jamroziak, Krzysztof
    ADVANCES IN MEDICAL SCIENCES, 2019, 64 (02): : 349 - 355
  • [4] Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience
    Byun, Ja Min
    Yoon, Sung-Soo
    Koh, Youngil
    Kim, Inho
    Jo, Jaemin
    Park, Hyunkyung
    Lee, Jeong-Ok
    Lee, Jiyun
    ANTICANCER RESEARCH, 2019, 39 (09) : 5165 - 5170
  • [5] Real world single-centre experience of daratumumab monotherapy in heavily pretreated relapsed/ refractory multiple myeloma
    Sanchez, I.
    Lam, H. P. J.
    Milner, G.
    El-Najjar, I.
    Sachchinanantham, S.
    Gleeson, M.
    Kazmi, M.
    Bailey, K.
    Benjamin, R.
    Cuthill, H.
    Yuen, L.
    Streetly, M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 168 - 168
  • [6] Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and Sirius
    Usmani, Saad Z.
    Nahi, Hareth
    Weiss, Brendan M.
    Bahlis, Nizar J.
    Belch, Andrew
    Lokhorst, Henk M.
    Voorhees, Peter M.
    Richardson, Paul G.
    Uhlar, Clarissa
    Wang, Jianping
    Qi, Ming
    Lonial, Sagar
    BLOOD, 2017, 130
  • [7] Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma
    Dimopoulos, Meletios-Athanasios
    Richardson, Paul
    Lonial, Sagar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 460 - 473
  • [8] Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
    Usmani, Saad Z.
    Nahi, Hareth
    Plesner, Torben
    Weiss, Brendan M.
    Bahlis, Nizar J.
    Belch, Andrew
    Voorhees, Peter M.
    Laubach, Jacob P.
    van de Donk, Niels W. C. J.
    Ahmadi, Tahamtan
    Uhlar, Clarissa M.
    Wang, Jianping
    Feng, Huaibao
    Qi, Ming
    Richardson, Paul G.
    Lonial, Sagar
    LANCET HAEMATOLOGY, 2020, 7 (06): : E447 - E455
  • [9] REAL-WORLD RESULTS OF DARATUMUMAB MONOTHERAPY IN HEAVILY PRETREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN POLAND: A PROSPECTIVE OBSERVATIONAL STUDY OF THE POLISH MYELOMA GROUP
    Salomon-Perzynski, A.
    Walter-Croneck, A.
    Usnarska-Zubkiewicz, L.
    Dytfeld, D.
    Zielinska, P.
    Wojciechowska, M.
    Holojda, J.
    Robak, P.
    Pasternak, A.
    Knopinska-Posluszny, A.
    Hawrylecka, D.
    Wojtowicz, M.
    Szeremet, A.
    Osowiecki, M.
    Mordak-Domagala, M.
    Zaucha, J. M.
    Giannopoulos, K.
    Warzocha, K.
    Jamroziak, K.
    HAEMATOLOGICA, 2017, 102 : 517 - 517
  • [10] Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma
    Beksac, Meral
    Aydin, Yildiz
    Goker, Hakan
    Turgut, Mehmet
    Besisik, Sevgi Kalayoglu
    Cagirgan, Seckin
    Tuglular, Tulin
    Vural, Filiz
    Yagci, Munci
    Alacacioglu, Inci
    Aytan, Pelin
    Goksoy, Hasan Sami
    Gulbas, Zafer
    Gunes, Ahmet Kursad
    Gurkan, Emel
    Hacioglu, Sibel Kabukcu
    Karti, Suleyman Sami
    Kaynar, Leylagul
    Ozdogu, Hakan
    Paydas, Semra
    Solmaz, Soner
    Sonmez, Mehmet
    Tekgunduz, Emre
    Yildirim, Rahsan
    Ilhan, Osman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (08): : E474 - E484
12345